BR112021023198A2 - Antagonistas do sistema de complemento para uso em métodos de tratamento de neuropatias paraproteinêmicas - Google Patents
Antagonistas do sistema de complemento para uso em métodos de tratamento de neuropatias paraproteinêmicasInfo
- Publication number
- BR112021023198A2 BR112021023198A2 BR112021023198A BR112021023198A BR112021023198A2 BR 112021023198 A2 BR112021023198 A2 BR 112021023198A2 BR 112021023198 A BR112021023198 A BR 112021023198A BR 112021023198 A BR112021023198 A BR 112021023198A BR 112021023198 A2 BR112021023198 A2 BR 112021023198A2
- Authority
- BR
- Brazil
- Prior art keywords
- paraproteinemic
- complement system
- neuropathies
- treating
- methods
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3084—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated gangliosides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/6408—Serine endopeptidases (3.4.21)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21043—Classical-complement-pathway C3/C5 convertase (3.4.21.43)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Cell Biology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1907153.9A GB2584105B (en) | 2019-05-21 | 2019-05-21 | Methods of treating neuropathy |
| PCT/EP2020/064234 WO2020234432A1 (en) | 2019-05-21 | 2020-05-21 | Antagonists of the complement system for use in methods of treating paraproteinemic neuropathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021023198A2 true BR112021023198A2 (pt) | 2022-01-04 |
Family
ID=67385155
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021023198A BR112021023198A2 (pt) | 2019-05-21 | 2020-05-21 | Antagonistas do sistema de complemento para uso em métodos de tratamento de neuropatias paraproteinêmicas |
Country Status (21)
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL3893924T3 (pl) * | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
| CN117597353A (zh) * | 2021-03-18 | 2024-02-23 | 艾菲洛之克公司 | 抗因子c3的sac7d变体及其治疗补体介导疾患的医疗用途 |
| EP4308591A4 (en) * | 2021-03-18 | 2025-04-02 | Affilogic | POLYPEPTIDES FOR COMPLEMENT INHIBITION |
| EP4059949A1 (en) * | 2021-03-18 | 2022-09-21 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| US20240166692A1 (en) * | 2021-03-18 | 2024-05-23 | Affilogic | Anti-factor c3 sac7d variants and their medical use for treating complement-mediated disorders |
| MX2024008273A (es) * | 2021-12-30 | 2024-07-19 | Annexon Inc | Composiciones y metodos para el tratamiento de la enfermedad de huntington. |
| MA71448A (fr) * | 2022-07-14 | 2025-04-30 | argenx BV | Régimes posologiques pour le traitement d'une neuropathie motrice multifocale (nmm) |
| EP4676952A2 (en) * | 2023-03-07 | 2026-01-14 | The Cleveland Clinic Foundation | Human complement component 2 binding molecules |
| WO2025146509A1 (en) * | 2024-01-05 | 2025-07-10 | argenx BV | Methods of treating multifocal motor neuropathy (mmn) |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| US8501705B2 (en) * | 2003-09-11 | 2013-08-06 | The Board Of Regents Of The University Of Texas System | Methods and materials for treating autoimmune and/or complement mediated diseases and conditions |
| WO2008030505A2 (en) * | 2006-09-05 | 2008-03-13 | Alexion Pharmaceuticals, Inc. | Methods and compositions for the treatment of antibody mediated neuropathies |
| GB0617734D0 (en) * | 2006-09-08 | 2006-10-18 | Evolutec Ltd | Method of treating peripheral nerve disorders |
| LT3028716T (lt) * | 2006-10-10 | 2020-12-10 | Regenesance B.V. | Komplemento slopinimas nervų regeneracijos pagerinimui |
| JP6223659B2 (ja) * | 2008-11-10 | 2017-11-01 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | 補体関連障害を処置するための方法および組成物 |
| WO2010056399A1 (en) * | 2008-11-17 | 2010-05-20 | Incode Biopharmaceutics, Inc. | Method and composition for modulating the immune system and various inflammatory conditions comprising complement depletors |
| PL2753636T3 (pl) * | 2011-09-07 | 2020-05-18 | The Trustees Of The University Of Pennsylvania | Analogi kompstatyny o ulepszonych właściwościach farmakokinetycznych |
| CN102949719A (zh) * | 2012-04-28 | 2013-03-06 | 上海市徐汇区中心医院 | 静脉注射免疫球蛋白抑制霍乱毒素和半乳糖凝集素-1结合到神经节苷脂gm1 |
| WO2014096958A1 (en) * | 2012-11-02 | 2014-06-26 | Academisch Medisch Centrum | Inosine monophosphate and salts thereof for use in the treatment of complement-related disorders |
| EP2997045A4 (en) * | 2013-05-15 | 2016-11-23 | Annexon Inc | ANTI-FACTOR C1S ANTIBODIES OF THE COMPLEMENT AND USES THEREOF |
| US9944717B2 (en) | 2013-05-23 | 2018-04-17 | Broteio Pharma B.V. | Binding molecules that bind human complement factor C2 and uses thereof |
| WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
| PL3215527T3 (pl) * | 2014-11-05 | 2025-04-28 | Annexon, Inc. | Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie |
| CN108026134A (zh) * | 2015-09-16 | 2018-05-11 | 巴塞尔大学 | 结合抗糖鞘脂糖蛋白表位抗体的碳水化合物配体 |
| FI3380518T3 (fi) * | 2015-11-24 | 2026-05-29 | Annexon Inc | Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä |
| WO2017196960A1 (en) * | 2016-05-10 | 2017-11-16 | Annexon, Inc. | Anti-complement factor c4/c4b antibodies and uses thereof |
| SG11201907583TA (en) * | 2017-03-14 | 2019-09-27 | Bioverativ Usa Inc | Methods for treating complement-mediated diseases and disorders |
| CA3078971A1 (en) * | 2017-11-01 | 2019-05-09 | Alnylam Pharmaceuticals, Inc. | Complement component c3 irna compositions and methods of use thereof |
| PL3893924T3 (pl) * | 2018-12-13 | 2025-01-13 | argenx BV | Przeciwciała przeciwko ludzkiemu czynnikowi c2b dopełniacza i sposoby zastosowania |
-
2019
- 2019-05-21 GB GB1907153.9A patent/GB2584105B/en active Active
-
2020
- 2020-05-21 BR BR112021023198A patent/BR112021023198A2/pt unknown
- 2020-05-21 CA CA3138401A patent/CA3138401A1/en active Pending
- 2020-05-21 AU AU2020279543A patent/AU2020279543B2/en active Active
- 2020-05-21 HU HUE20729653A patent/HUE072743T2/hu unknown
- 2020-05-21 CN CN202080037596.6A patent/CN114269382B/zh active Active
- 2020-05-21 DK DK20729653.4T patent/DK3972643T3/da active
- 2020-05-21 MA MA71752A patent/MA71752A/fr unknown
- 2020-05-21 PL PL20729653.4T patent/PL3972643T3/pl unknown
- 2020-05-21 EA EA202193189A patent/EA202193189A1/ru unknown
- 2020-05-21 FI FIEP20729653.4T patent/FI3972643T3/fi active
- 2020-05-21 JP JP2021569042A patent/JP7607590B2/ja active Active
- 2020-05-21 EP EP25159620.1A patent/EP4570316A3/en active Pending
- 2020-05-21 PT PT207296534T patent/PT3972643T/pt unknown
- 2020-05-21 CN CN202410047987.6A patent/CN118021970A/zh active Pending
- 2020-05-21 MX MX2021014170A patent/MX2021014170A/es unknown
- 2020-05-21 EP EP20729653.4A patent/EP3972643B1/en active Active
- 2020-05-21 SG SG11202112232YA patent/SG11202112232YA/en unknown
- 2020-05-21 ES ES20729653T patent/ES3035736T3/es active Active
- 2020-05-21 KR KR1020217039139A patent/KR20220010505A/ko active Pending
- 2020-05-21 LT LTEPPCT/EP2020/064234T patent/LT3972643T/lt unknown
- 2020-05-21 WO PCT/EP2020/064234 patent/WO2020234432A1/en not_active Ceased
-
2021
- 2021-11-11 IL IL288010A patent/IL288010A/en unknown
- 2021-11-18 MX MX2025014486A patent/MX2025014486A/es unknown
-
2024
- 2024-12-17 JP JP2024220534A patent/JP2025038109A/ja active Pending
- 2024-12-18 JP JP2024221343A patent/JP2025041724A/ja active Pending
-
2026
- 2026-07-01 AU AU2026205212A patent/AU2026205212A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021014170A (es) | Antagonistas del sistema de complemento para uso en metodos de tratamiento de neuropatias paraproteinemicas. | |
| BR112021017350A2 (pt) | Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp | |
| JOP20200082B1 (ar) | علاج متلازمة الكروموسوم إكس الهش باستخدام الكانابيديول | |
| BR112016015718A2 (pt) | Processo de purificação de aminoácidos aromáticos | |
| BR112018075516A2 (pt) | purificação de anticorpos multiespecíficos | |
| GEAP202616896A (en) | Combinations for the treatment of cancer | |
| BRPI0907135B8 (pt) | uso de um anticorpo antagonista anti-cgrp para a prevenção e/ou tratamento de dor de câncer crônica | |
| EP4234013A3 (en) | Methods for treating or preventing atherosclerosis by administering an inhibitor of angptl3 | |
| EA201270184A1 (ru) | Лечение расстройств печени ингибиторами pi3k | |
| BR112014018481A2 (pt) | anticorpo monoclonal ou policlonal ou um fragmento de ligação a antígeno do mesmo, polinucleotídeo, anticorpo monoclonal, vetor, hibridoma, anticorpo, hibridoma 5166-2 e/ou 5166-9, anticorpo ou fragmento de ligação a antígeno, composição farmacêutica, uso do anticorpo ou fragmento de ligação a anticorpo, método para tratar câncer, método para diagnosticar câncer em um indivíduo, anticorpo, método, composição ou uso | |
| AR088289A1 (es) | Composiciones para el tratamiento de la artritis reumatoide y metodos para su utilizacion | |
| CY1110435T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια οφθαλμικων καταστασεων με παραγωγα ρετινολης | |
| EA201891388A1 (ru) | Ингибиторы калликреина плазмы и их применение для лечения обострения наследственного ангионевротического отека | |
| BR112014021498A2 (pt) | composto, composição e método para tratar uma doença associada com formação de dna circular covalentemente fechado | |
| BR112014012607A2 (pt) | métodos de tratamento usando um inibidor de interferon gama | |
| EA201490875A1 (ru) | Производное аминоалкилзамещенного n-тиенилбензамида | |
| BR112018000771A2 (pt) | anticorpos que se ligam à sortilina e inibem a ligação de progranulina, composições farmacêuticas, preparações dos mesmos, uso de anticorpos, kit e método de prevenção ou tratamento de uma doença associada a níveis diminuídos de pgrn | |
| BR112021021537A2 (pt) | Composições e métodos que usam um ou mais aminoácidos indutores de autofagia para potencializar o efeito músculo-esquelético de um ou mais aminoácidos anabólicos | |
| EP4678660A3 (en) | Antibody against activin receptor type ii receptor for use in treating heart failure | |
| BR112015022321A2 (pt) | método para purificação de uma proteína | |
| BR112018073553A2 (pt) | medicamento e composição farmacêutica para a prevenção ou tratamento de fibromialgia ou sintomas funcionais associados com fibromialgia, método para prevenir ou tratar fibromialgia ou sintomas funcionais associados com fibromialgia em um indivíduo, e, uso de um composto carbamato. | |
| HK1254954A1 (zh) | Lpt-723和免疫检查点抑制剂组合物及其治疗方法 | |
| AR107983A1 (es) | Métodos para tratar eventos adversos gastrointestinales relacionados con el sistema inmunitario en tratamientos de combinación anti-ctla4 anti-pd-1 | |
| MX2025003476A (es) | Anticuerpos anti-il-27 y usos de los mismos | |
| BR112021020424A2 (pt) | Compostos e métodos para tratamento de distúrbios inflamatórios |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] |